platform expans initi coverag
outperform pt
initi coverag outperform rate pt believ
engin toxin bodi etb platform offer differenti moa base forc
intern antibodi fragment directli ribosom shiga-lik
toxin mechan action result disrupt protein synthesi direct
cell-kil expect novel moa offer clinic advantag monotherapi
refractori set receptor express maintain despit resist prior
treatment target receptor combin therapi
frontlin potent substitut antibodi therapeut novel target
amen antibodi due challeng intern anticip etb
attract pharma expect partnership contribut news
etb fuse antibodi fragment shiga-lik toxin slt-a known forc
cell intern enzymat inactiv ribosom import
insight identifi amino acid substitut slt-a reduc elimin
immunogen backbon combin uniqu moa antibodi
fragment intend improv tumor specif
expect activ relapsed/refractori multipl myeloma patient
follow progress antibodi daratumumab base potent
activ cell co-express purport mechan
resist daratumumab model call sale
peak sale greater
view develop r/r dlbcl clinic valid etb
moa rapid path commerci base orr endpoint support
fda file clinic relev base poor respons avail salvag
option expect gener peak sale primarili dlbcl
relapse/refractori nhl patient
view present top-lin phase ii data r/r high-risk dlbcl
patient potenti addit corpor partnership signific
mileston
novel moa associ etb manag team extens
busi develop experi view well posit
seek addit partnership may offer materi upsid current
financi outlook view takeda partnership templat futur
transact mileston plu royalti target
year price histori
develop
target therapeut treat cancer
base engin toxin bodi
analyst certif import disclosur see disclosur
target receptor known clinic relev treatment
cancer new mechan action etb deriv
shiga-llk toxin support portfolio
therapi treatment refractori diseas import
compound valid platform support pt
etb partner takeda
posit address grow market daratumumab-
resist multipl myeloma patient clean
immunogen profil phase expect biotech
compani licens etb platform
second-gener etb elicit clinic
immunogen hematolog malign includ multipl
express retain signific portion patient
progress daratumumab creat refractori market
demonstr adequ efficaci approv
relapse-refractori dlbcl use frail patient inelig
takeda file ind potenti disclos
detail develop strategi multipl myeloma
compani announc one etb partnership target
outsid intern develop focu
potenti interim updat registr phase ii studi
relapse-refractori dlbcl
immunogen profil etb adequ develop drug
solid tumor includ etb-bas inhibitor
econom solid tumor forecast
dlbcl efficaci superior therapi
result use treatment nave patient frail car-t
partnership one solid tumor indic allow
develop multipl cancer indic parallel
demonstr immunogen phase develop
de-immun
new gener bispecif antibodi offer better safeti wider
therapeut window lead robust competitor etb
partner takeda provid adequ support time
develop
price target base dcf analysi assum discount rate million share fulli dilut basi termin
year long-term growth rate
risk clinic trial failur phase ii program relapse-refractori dlbcl delay file ind
multipl myeloma disrupt manufactur suppli chain includ scale patent protect etb
platform invalid legal challeng de-immun process underpin etb reduc immunogen reduct
adequ prevent clinic relev advers event
note see stock trade specul appropri risk toler investor
initi coverag outperform
initi coverag inc outperform rate
price target believ compani engin toxin bodi etb platform offer
differenti mechan action moa base forc intern antibodi
fragment directli ribosom shiga-lik toxin slt-a mechan action
result disrupt protein synthesi direct cell-kil
compani lead product target b-cell enter phase ii
registr studi relapse/refractori dlbcl interim data possibl
model call achiev peak sale target
molecul incorpor mtem second-gener scaffold improv de-
immun slate begin clinic develop model call
sale exceed achiev peak sale multipl myeloma
addit anticip novel moa etb attract pharmaceut
compani expect partnership import contributor near-term news
flow long-term valu creation price target base dcf
analysi assum discount rate million share fulli dilut basi
termin year long-term growth rate
initi biotim outperform outperform also
etb platform offer novel mechan action oncolog
etb fuse antibodi fragment slt-a known forc cell intern
enzymat inactiv ribosom import insight identifi
amino acid substitut slt-a termin bind configur reduc
elimin immunogen shiga toxin combin moa antibodi fragment
intend improv tumor specif howev unlik adc monoclon antibodi
induc cytotox adcc cdc etb induc direct cell-kil
disrupt protein synthesi invest thesi base least
part expect moa offer clinic advantag refractori set
monotherapi receptor express maintain despit resist prior
treatment target receptor ie combin therapi
front-lin potent substitut antibodi therapeut novel
target amen tradit antibodi drug due challeng intern
develop initi focus hematolog malign patient low
immunogen risk applic solid tumor well view
standard refractori dlbcl
fusion protein compos antibodi fuse engin
form slt-a expect molecul offer potenti high tumor specif akin
differenti mechan cytotox base disrupt protein
synthesi antibodi rituxan believ induc cytotox
indirect process antibody-depend cellular cytotox adcc
inactiv ribosom result disrupt protein synthesi direct cytotox
importantli multipl studi demonstr lymphoma patient
progress diseas follow treatment antibodi retain high level
receptor express believ strong rational suggest
altern moa may offer potent clinic activ refractori patient well-
valid mechan b-cell regul importantli current standard care
relapsed/refractori diffus larg b-cell lymphoma dlbcl base cur intent
believ orr endpoint singl phase ii studi may adequ
support fda file model call captur us
relapsed/refractori dlbcl market patient peak revenu
target sale potenti
mtem advanc second-gener etb fulli de-immun
scaffold similar etb-bas compound demonstr
potent cell-kil activ tumor cell picomolar valu
improv slt-a immunogen compar first-gener scaffold use
vivo activ clinic valid xenograft model potenti synergi
pomalidomid addit show high-affin bind recombin
protein well myeloma cell line expect similar
profil improv antibodi bind support potenti
combin therapi daratumumab expect partner takeda submit
investig new drug applic ind initi phase i/ii
develop relapsed/refractori multipl myeloma model call launch
us outsid us forecast translat
sale peak sale greater
strong balanc sheet fund multipl catalyst
cash balanc end septemb believ compani
adequ access capit fund oper believ
posit complet three import mileston requir addit financi
resourc includ present interim phase ii data
relapsed/refractori high-risk dlbcl patient earli matur data
initi phase develop treatment relapsed/refractori
multipl myeloma potenti busi develop includ
develop partnership larg pharmaceut compani potenti out-
licens right certain countri outsid us
busi develop drive takeda deal offer templat
novel mechan action associ etb lucr initi partnership
takeda provid templat futur transact mileston plu royalti
equiti invest manag team extens busi develop
experi imclon system lead biotech compani view
well posit seek addit partnership may offer materi upsid
current financi outlook expect futur transact narrow scope
includ specif antibodi target outsid compani intern focu scope
may narrow view econom contribut could signific
june takeda sign agreement provid mileston
undisclos tier royalti estim mid single-digit low double-digit
right combin etb platform two takeda antibodi target takeda also agre
make equiti invest expect partnership
agreement also retain manufactur right offer potenti captur
econom equival mid single-digit royalti transfer price view
evofosfamid prodrug bromo-isophosphoramid mustard br-ipm dna
alkyl agent design preferenti activ hypox region commonli present
tumor microenviron drug fail phase program
treatment pancreat develop howev explor two capital-effici
path maxim valu program includ investigator-sponsor studi
combin ipilimumab advanc solid tumor potenti japanes
develop pancreat cancerlik partner base prior fail phase
develop includ evofosfamid forecast revisit
assumpt follow preliminari efficaci analysi phase combin studi
success partner japanes right
price target share base discount cash flow dcf model
sale treatment relapsed/refractori dlbcl
relapsed/refractori multipl myeloma modest econom partner
includ potenti revenu earlier-lin combin therapi off-label use
indic therapi approv account
potenti long-term valu mtem etb technolog includ early-stag program
form higher long-term revenu growth rate
model call compani commerci asset unit state
field sale forc repres expect seek commerci
partner outsid us receiv econom equival net royalti
compani achiev profit begin pay
tax effect tax rate forecast call total revenu
last year dcf model roughli gross revenu us
sale remaind intern market final year dcf
valuat forecast free cash flow driven sale total
share count million fulli dilut basi
oppenheim co inc estim compani document
view discount rate lower typic discount rate
oncolog diseas compani phase develop appropri given lower-risk
develop strategi pursu clinic well-valid target rel strong
balanc sheet cash estim long-term revenu growth rate
basi point standard long-term growth rate biotechnolog
compani believ growth rate appropri given mtem commit
invest slt-a technolog support intern pipelin next-gener oncolog
candid potenti long-term upsid multipl pharmaceut partnership
share count million assum cash convers roughli million option
warrant model call current cash balanc fund oper
increment capit requir roughli achiev profit
next month view present top-lin phase ii data
relapsed/refractori high-risk dlbcl patient potenti addit corpor
partnership signific near-term mileston addit encourag
investor focu advanc clinic develop
relapsed/refractori multipl myeloma import step toward valid mtem
second-gener etb platform offer potenti develop potent de-
immun molecul accept ind potenti could serv
de-risk event second-gener etb candid
oppenheim co inc estim compani document
base known activ compound treatment relapsed/refractori
nhl initi phase i/ib studi februari promis earli sign
efficaci dlbcl led manag decemb open expans
data patient expect phase ii dose present
american societi clinic oncolog meet demonstr partial
respons pr expect see data addit patient maintain
object respons rate orr adequ advanc program
registr studi view believ approv relapsed/refractori set could
base single-arm phase ii studi orr primari endpoint
addit initi two phase i/ii studi evalu
treatment-nav dlbcl patient high-risk diseas due chemo-intoler
chemo-inelig double-hit double-express mutat top-lin
data treatment-nav dlbcl expect given potenti cur intent
treatment-nav set view approv high-risk treatment-
nave dlbcl like base overal surviv endpoint versu standard care
requir consider longer time line relapsed/refractori set
 incom work free cash growth cash phase ii studi combin phase ii trial r/r dlbcl revlim phase ii studi earli stage dlbcl ind etb takeda file ind etb ind etb antigen seed addit target takeda outperform
term develop expect ind file earli
despit increasingli competit landscap multipl myeloma view fda
still amen approv potent drug relapsed/refractori set base
phase ii studi demonstr orr point refer
first-gener antibodi daratumumab approv base orr
median month
last note invest thesi view pipelin expans partner
larg pharmaceut compani expertis antibodi develop key
valu driver share path rapid pipelin expans expect
futur deal focu either novel target valid target offer challeng
antibodi optim expect partner includ current pipelin program
target previous defin prioriti in-hous develop
visibl timelin specif event believ
complet one deal next month could serv import catalyst
share
incorpor februari pharma focu develop
novel mechan action therapeut modal well-defin oncolog
target compani program base
compani enjoy signific non-dilut financi support state
texa includ cprit grant support develop mtem
primari research manufactur facil austin compani also maintain
execut offic jersey citi nj provid access clinic oper profession
privat held compani fund rel narrow syndic
ventur investor order improv access capit acceler clinic
develop august compani complet revers
merger public trade shell compani threshold pharmaceut concurr
equiti financ new public market investor threshold asset includ
cash evofosfamid hypoxia-induc prodrug bromo-
isophosphoramid mustard br-ipm expect substanti futur equiti capit
financ develop mtem legaci asset futur develop
evofosfamid fund non-dilut structur corpor partner
importantli found execut scientist continu work
view continu asset compani seek scale multipl clinic
program insid control roughli vote stock
etb platform pipelin overview
develop pipelin oncolog drug base engin toxin bodi
platform may offer sever advantag antibodi adc biolog
advantag base potenti induc intern cancer cell
de-immun backbon offer potenti reduc adapt innat
immun respons result greater potenc novel mechan action base
ribosom inactiv protein synthesi disrupt
etb consist antibodi fragment fuse engin shiga-lik toxin a-
subunit slt-a platform base observ nativ shiga-lik toxin
contain subunit unit subunit induc receptor intern
exact mechan forc intern well understood research
suggest lipid raft may enabl process engin slt-a etb roughli
amino acid sequenc sequenc modifi nativ
insid cell subunit irrevers bind ribosom result disrupt
protein synthesi cell destruct process similar well
character mechan pseudomona diphtheria unit nativ shiga
toxin bind typic intern cell
mtem etb compound seek maintain activ mechan intern
subunit replac unit antibodi fragment enhanc
specif cell target identifi optim antibodi fragment complex
tradit monoclon antibodi antibodi highest affin
alway optim candid accord manag roughli third antibodi
evalu mtem lead program fold properli fuse slt-a
manag develop certain know-how select antibodi fold properli
process still fulli understood
first-gener second-gener compound includ
surfac target strateg level goal program
demonstr differenti potenc associ uniqu mechan action
control known biolog activ antibodi bind target
takeda disclos antibodi fragment expect
compound incorpor proprietari antibodi fragment
fusion protein compos variabl region heavi vh light
vl chain antibodi connect via short linker peptid form single-
chain variabl fragment scfv bind domain genet fuse engin
form slt-a first-gener etb scaffold partial de-immun
believ potenti immunogen may challeng solid tumor view
advanc b-cell malign patient typic immunocompromis unlik
develop clinic import immunogen
contain fragment crystalliz fc portion antibodi
cell-kil activ depend tumor microenviron either host antibody-
depend cellular toxic adcc complement-depend cytotox cdc
mechan lymphoma
base refin end terminu bind slt-a backbon
remov epitop second-gener etb appear fulli de-immun
specif present data medic confer evalu
immunogen profil etb incorpor either first-gener scaffold
second-gener scaffold non-human primat etb
serum exposur greater follow first-dos
etb detect hour post-dos versu hour furthermor mt-
detect post-sixth dose lower limit quantif
despit higher serum exposur lower anti-etb igg antibodi
studi day lower anti-drug antibodi respons observ non-human primat
also demonstr mice total believ data confirm improv
immunogen profil mtem second-gener scaffold
current disclos program mtem pipelin exclud base
second-gener scaffold
compani third-gener platform build upon de-immun second-
gener etb genet fuse mhc class foreign antigen scaffold mark
etb intern cell target cytotox lymphocyt mediat cell lysi
initi work focus antigen deriv human cytomegaloviru cmv given
high rate cmv infect potenti recruit robust pre-exist
respons tumor cell antigen present requir de novo protein
synthesi expect immune-driven lysi complementari slt-a domain-
septemb disclos agreement takeda co-
develop next-gener compound multipl myeloma base
etb platform plan advanc compound develop jointli
takeda intern develop up-front payment believ
agreement valid etb platform altern moa deliveri
antibodi therapeut expect remain activ pharmaceut partner
etb-bas program furthermor view agreement signal
takedaon leader multipl myeloma researchthat remain
import target alongsid bcma compound demonstr impress potenc
recent clinic trial base data literatur suggest mani multipl
myeloma patient progress daratumumab retain express view
strong rational develop novel mechan target second-
third-lin daratumumab failur last publicli avail data
compound develop takeda potenti limit prior-gener anti-
etb compound includ competit bind daratumumab
would prevent co-administr potenc profil appear less
robust data bcma compound would expect improv one
product characterist
takeda agreement co-develop partnership regulatori
approv takeda respons commerci expens
opt co-develop point clinic develop reduc
downstream econom receiv sign term co-develop
agreement elig mileston tie
develop regulatori mileston sale milestonesand tier
royalti low double-digit compani opt fund co-
develop agreement econom reduc mileston payment
develop regulatori mileston sale milestonesand
tier product sale royalti high single-digit low doubl digit respons
futur manufactur disclos
assum shift develop mtem delay ind file
month late earli respons
half clinic develop expens expect takeda run larger phase
develop program would like plan without partnership
base case assum cash spend product candid
larg unchang partnership appli remain balanc
grant cprit portion develop expens takeda
upsid takeda target
june enter etb collabor
agreement view could serv templat futur partnership
pharmaceut biotech compani deal includ provis allow
limit scope target outsid core focu mtem intern pipelin access
fulli optim antibodi fragment develop partner retent
process develop support minim risk immunogen improv
manufactur yield believ structur allow retain access
increment learn regard applic shiga-lik toxin gain access
proprietari antibodi technolog view one current weak
busi model time gain broader access antibodi
intern develop acquisit antibodi librari collabor
agreement antibodi librari compani expect manag becom
select partner discuss
take takeda partnership serv templat futur transact
addit attract econom partner transact offer need access
larger pool optim antibodi candid
june takeda enter multi-target licens agreement
develop etb takeda-design target base takeda-
provid target moieti agreement focus two preclin program
view econom attract sharehold specif takeda make
equiti invest pay develop
commerci mileston evenli split two program
mileston payment includ undisclos up-front fee payment
aggreg option exercis period end phase develop post-
option exercis elig addit mileston payment
also pay undisclos tier royalti futur sale estim mid
single-digit low double-digit japanes drugmak design one board
exhibit overview econom takeda option deal
oppenheim co inc estim compani document
parti grant non-exclus intellectu properti right relev
technolog work exclus takeda target cover
agreement specif target disclos agreement provid takeda option
acquir exclus licens manufactur commerci etb
design target manufactur etb phase clinic trial howev
given limit avail bacteri express product capac signific
know-how involv captur commerci viabl yield product toxin
shiga-lik toxin strong rational support commerci
manufactur view could provid signific econom upsid
soc refractori dlbcl
first-gener etb candid nanomolar affin clinic
valid target treatment lymphoma autoimmun diseas
receptor sever characterist attract clinic valid etb
platform characterist includ non-intern receptor
suscept tradit direct cell-kil modal chemotherapy-bas antibodi
drug conjug b-cell nhl patient express
evid mani patient relaps progress exist therapi retain
model call peak sale potenti relapsed/refractori dlbcl
patient base annual treatment cost averag month
therapi assum market penetr salvag set use mt-
high-risk treatment-nav dlbcl patient indic could
offer materi upsid potenti forecast receiv grant
cancer prevent research institut texa cprit partial off-set develop
fusion protein compos variabl region vh vl chain
antibodi connect via short linker peptid form single-chain variabl
fragment bind domain fuse engin form slt-a mention
slt-a demonstr activ forc intern self-rout
cytosol irrevers bind ribosom result enzymat inactiv
ribosom molecul offer potenti high tumor specif akin
differenti mechan cytotox base disrupt protein synthesi
antibodi rituxan believ induc cytotox
indirect process antibody-depend cellular cytotox
take partial de-immun first-gener scaffold seem unlik gener
clinic relev immunogen advanc lymphoma patient like
appropri autoimmun indic
rituxan wide use hematolog autoimmun diseas expect
immunogen profil limit use advanc lymphoma patient
specif incorpor first-gener etb scaffold appear
partial de-immun advanc nhl dlbcl patient sever compromis
immun system highli unlik mount clinic relev immunogen
respons partial de-immun slt-a view initi clinic data dlbcl
patient suggest low occurr non-neutr anti-drug antibodi accord
howev immunogen risk younger rel healthi rheumatoid
arthriti lupu patient could signific view
exhibit mechan action
robinson engin toxin bodi target non-hodgkin lymphoma abstract
differenti moa support develop relapsed/refractori dlbcl
mention requir adcc complement-depend
cytotox complement-medi lysi induc cytotox
mechan regul tumor microenviron view may
contribut develop resist given differenti moa anticip mt-
may offer differenti potenti favor resist profil particularli
appropri relapsed/refractori patient
take twenti percent-plu orr phase ib studi relapsed/refractori dlbcl
support begin phase ii studi believ fda approv
relapsed/refractori set may possibl base singl phase ii studi
primari endpoint orr
term pipelin expans initi phase i/ii develop mt-
high-risk treatment-nav dlbcl patient base larg popul chemo-
intoler chemo-inelig first-lin set lesser extent potenti activ
double-hit dlbcl express mutat poor prognosi
take develop first-lin set view would like requir
improv overal surviv versu standard care soc view
develop time line significantli longer relapse/refractori set
march world summit europ report import updat
three patient program dlbcl updat includ
addit pr expans cohort r-chop refractori patient preliminari
respons rate around refin dose improv toler
phase ib develop includ nine dlbcl patient low serum level
rituximab mg/ml dose rang mcg/kg mcg/kg updat
includ three dlbcl patient dose expans cohort recommend dose
result includ one pr reduct tv one stabl diseas one
progress diseas pr patient femal prior pr six-
month durat benefit inhibitor tazemetostat also refractori
r-chop prior exposur r-eshap regimen complet molecular respons
importantli expans protocol allow patient stay drug beyond limit
howev two three patient expans cohort experienc dose interrupt
dose one patient record grade headach arthralgia myalgia
second record undisclos grade advers event believ
toler profil dose reason advanc dlbcl patient
popul abund caution desir differenti
therapi base toler studi protocol amend recommend dose
mcg/kg mcg/kg
would note three patient analysi much higher bodi mass
typic lymphoma patient kg start dose
absolut dose futur enrol cap mg
net view toler profil appear accept draw
relationship dose advers event among three patient confound
phase i/ib studi evalu safeti toler treatment
relapsed/refractori b-cell malign patient progress nhl lesion
cll achiev initi respons standard antibody-contain front-lin
treatment regimen elig biolog therapi chemotherapi and/or
autolog stem cell transplant asct enrol onto dose-escal portion
clinic trial initi data first patient evalu efficaci present
includ two partial respons base earli efficaci result dlbcl
initi phase ib expans cohort enrol addit relapsed/refractori
dlbcl patient recommend phase ii dose
patient enrol onto sequenti cohort
base toxic
open cohort patient receiv cycl patient receiv dose
infus everi day hour total day first dose cycl
defin day addit cycl day open extens
studi enabl addit dose cycl elig patient total cycl
primari endpoint maximum toler dose recommend phase ii
dose secondari outcom measur includ safeti toler pk profil mt-
tumor progress assess cycl
present interim data first patient enrol onto
studi includ dlbcl follicular lymphoma fl mantl cell lymphoma
mcl patient median age year median six year diagnosi
total patient clinic stage iv diseas notabl patient
prior therapi rang includ prior asct car-t
take phase studi reflect true salvag popul patient
stage stage iv diseas four prior therapi
regard orr two patient total low baselin serum achiev
pr dlbcl fl fl patient achiev complet metabol
respons underw asct total seven patient total achiev stabl
diseas mix partial respons among eight case progress diseas five
occur high baselin cohort data outlin exhibit
baselin serum level ng/ml appear posit impact orr
focu evalu exhibit display
patient-specif respons data patient low level
among patient treat recommend phase ii dose low baselin anti-
two patient complet least two cycl patient fl
achiev stabl diseas reduct post-cycl deepen
reduct post-cycl patient mcl diseas progress cycl patient
withdrew due progress prior complet cycl
assess done cycl death cycl unrel overal respons baselin serum baselin serum hamlin et al data first immunotoxin phase i/ib studi relapsed/refractori r/r non-hodgkin lymphoma nhl
exhibit orr subject baselin
hamlin et al data first immunotoxin phase i/ib studi relapsed/refractori r/r non-hodgkin
mention patient achiev complet metabol respons post-cycl
underw asct patient complet cycl achiev stabl
diseas patient enrol onto extend access portion studi maintain
stabl diseas throughout mix respons achiev patient prior
progress patient enrol onto arm withdrew due
toxic dose dose respect stabl diseas reduct
observ patient withdraw
pharmacokinet pharmacodynam profil
exposur dose proport exhibit dose-
depend reduct peripher b-cell high baselin rituximab level
ng/ml associ lower baselin cell count serum half-lif
hour short compar immunotoxin
exhibit cycl day pk baselin rituximab cell count
hamlin et al data first immunotoxin phase i/ib studi relapsed/refractori r/r non-hodgkin
base nomin infus cycl day sampl ng/mlb cell cells/ul cycl day outperform
exceed dose first two patient treat
demonstr sign symptom system inflammatori respons consist
capillari leak syndrom includ grade decreas serum albumin symptom
develop cycl non-lif threaten patient discontinu due
toxic event resolv dose cessat dose-limit toxic dlt
report six enrol patient complet cycl
time august cutoff safeti data avail patient
total advers event report includ seriou advers event
report patient common event outlin exhibit
includ peripher edema diarrhea myalgia cough fatigu constip nausea
report patient
seriou advers event occur least two patient includ thrombocytopenia
pneumonia hypercalcemia
hamlin et al data first immunotoxin phase i/ib studi relapsed/refractori r/r non-hodgkin
total advers seriou advers advers seriou advers event patientsoedema
american associ cancer research meet
present preclin data demonstr potenti monotherapi combin anti-
tumor activ vitro lymphoma model scid mice inject
daudi-luc cell via tail vein anim random group match
averag bioluminesc bli signal day receiv intraperiton
everi week total dose
demonstr reduc tumor burden compar vehicl control day
measur whole-bodi luminesc signal exhibit
exhibit demonstr reduc tumor burden day
robinson engin toxin bodi target non-hodgkin lymphoma abstract
separ xenograft model raji-luc tumor well toler
result statist signific surviv advantag
assess intern cell incub
rituxan mab minut minut minut
intern assess cpm strip cell surface-bound protein intern
cell-associ cpm bound and/or intern shown exhibit led
rapid intern greater proport intern compar
robinson engin toxin bodi target non-hodgkin lymphoma abstract
imid inhibitor vitro
combin studi evalu cell viabil daudi cell ki determin
sum ratio valu impli synergi lenalidomid
dose hour prior combinationsvenetoclax inhibitor
idelalisib inhibitor ibrutinib btk inhibitor administ concurr
robinson engin toxin bodi target non-hodgkin lymphoma abstract
shown exhibit synergist combin averag
inhibitori constant ki lenalidomid idelalisib ibrutinib venetoclax
respect
present data demonstr dose combin
sirolimu decreas anti-drug antibodi respons prolong serum
exposur improv b-cell deplet versu alon optim combin
regimen oral sirolimu load dose day follow mainten day
 cycl anti-drug antibodi detect relapse/refractori nhl
patient cycl phase develop
exhibit respons r/r nhl titer nhp
higgin et al combin sirolimu reduc anti-drug antibodi respons prolong drug exposur poster
co-administr oral sirolimu balb/c mice delay reduc mt-
igg anti-drug antibodi respons compar alon optim co-
administr regimen load dose day follow mainten
cycl group base igg anti-drug antibodi respons
studi day defin percentag control respons
exhibit igg anti-drug antibodi respons vehicl control group
higgin et al combin sirolimu reduc anti-drug antibodi respons prolong drug exposur poster
non-human primat co-administ oral sirolimu load dose
day mainten day compar vehicl control sirolimu
co-administr significantli reduc antibodi respons dose
day dose day compar control sirolimu co-
administr improv measur serum level day
nhp versu control co-administ nhp exhibit prolong pd
respons day nadir vs day greater decreas cell vs
exhibit co-administr sirolimu nhp
higgin et al combin sirolimu reduc anti-drug antibodi respons prolong drug exposur poster
regard safeti profil co-administr elev bodi temperatur
observ co-administ anim compar control common
advers event peripher edema diarrhea myalgia cough fatigu constip
dehydr hypoalbuminemia hyponatremia dysgeusia oropharyng pain
revenu sale
revenu forecast focus relapsed/refractori dlbcl base
known efficaci profil antibodi signific unmet need
chemotherapy-refractori patient elig stem cell transplant believ
rational clinic util treatment-nav patient inelig
doxorubicin also indicationsoncolog non-oncologyw
includ potenti sale revenu model last model segment revenu
us rest world row us market repres market
opportun base clear regulatori reimburs path us target
american diagnos nhl year accord american
cancer societi roughli nhl patient diagnos dlbcl
express approxim b-cell nhl cell result first-lin market
case annual
variou publish studi suggest dlbcl patient refractori
first-lin r-chop therapi furthermor patient ultim relaps
initi respons r-chop model focus approxim relaps
occur within five year roughli r-chop relapsed/refractori dlbcl
patient undergo asct follow high-dos chemotherapi assumpt
base contemporari experi coral studi
overal identifi target us relapsed/refractori dlbcl popul
patient model includ potenti use earlier line patient asct failur
believ conserv estim appropri due absenc clinic
data treatment-nav patient
model call captur target us r/r dlbcl
market base limit treatment altern expect price
annual per one-month treatment cycl us similar
model assum dose continu diseas progress believ
orr would minimum efficaci threshold support commerci
assum patient receiv monthli cycl averag cost
per patient us
seem like eventu partner row exchang econom
equival royalti net sale single-point estim
methodolog point includ partner mileston revenu model due
limit visibl time captur mileston econom higher royalti rate
futur sale
expect drug launch us outsid us
net forecast translat peak sale includ us sale
intern royalti gross sale
dlbcl market modelamerican diagnos nhl project growth nhl number nhl nhl patient dlbcl subtyp cell nhl dlbcl patient dlbcl refractori r-chop within first dlbcl patient relaps r-chop within first patient r/r r/r dlbcl patient inelig hd-asct salvag r/r dlbcl market dlbcl popul receiv patient script per per treatment per price per sale r/r dlbcl row gross revenu growth row sale revenu american cancer societi american societi clinic oncolog outperform
competit landscapefocu bispecif
multipl compound clinic develop focu
bispecif antibodi primari competit base potenti deliv t-cell
direct cell-kil activ gener believ bispecif compound face challeng
provid predict target affin relat potenti unexpect advers event
bispecif compound differ mechan action mtem
etb view compound directli competit success
develop one compound describ may reduc
address market compound earli clinic develop
view earli assess futur competit landscap
human full-length bispecif antibodi target
program phase develop cell malign open-label
dose escal phase studi design evalu safeti pk preliminari
efficaci without obinutuzumab relapse/refractori b-cell nhl
cll patient asct within previou day diseas exclud
patient receiv iv day cycl cohort day
cycl day subsequ cycl patient cohort
 receiv pretreat single-dos obinutuzumab day prior first
dose treatment continu cycl dose-escal continu
identif recommend phase ii dose point patient receiv
pk/pd profil obinutuzumab secondari measur includ orr
durat respons immunogen
hinge-stabil full length bispecif target antibodi
base isotyp modifi reduc fc bind regeneron report interim
phase monotherapi data dose-escal studi nhl cll patient
demonstr orr phase studi lymphoma patient evalu combin
therapi investig antibodi enrol patient
regeneron present data nhl cll patient
receiv monotherapi phase dose-escal studi nhl cll
patient enrol onto separ dose escal cohort dose iv
hour weekli dose everi week dose dose begin initi
start dose follow step-up dose
interim data includ nhldlbcl fl mcl patient
cll patient treat flat dose rang patient median
three prior therapi rang patient receiv median infus
rang total six patient remain initi treatment three complet dose
total patient discontinu due progress diseas subject decis
total four patient enter retreat includ two remain on-going
time data cutoff
anti-tumor activ measur ct scan achiev nhl patient includ
pr stabl diseas orr pr median durat day stabl
diseas maintain median day orr patient treat
two highest dose cohort total patient evalu pet total four
patient partial metabol respons median durat day cll
exhibit best percentchang baselin lesionnhl
et al phase studi bispecif monoclon antibodi patient b-cell malign
previous treat direct antibodi therapi abstract
drug concentr serum increas increas dose level concentr
vari across patient variat less higher dose level decreas
time therapi concentr notic accumul treatment durat
transient b-cell deplet observ patient measur circul b-cell
lowest dose interim cytokin analysi patient indic induc
cytokin releas increas lesser extent ifn-i note
magnitud cytokin respons typic correl symptomat infus relat
total patient report least seriou treatment-rel advers event
includ cytokin releas syndrom infus relat reaction total
patient aggress lymphoma die within day last dose due progress
protocol-defin dlt grade treatment-emerg event
patient discontinu due toxic
common treatment-emerg advers event includ pyrexia infus
tachycardia hypomagnesaemia hypotens grade higher
event occur patient includ infusion-rel reaction
hypotens event grade except patient grade
transaminas increas tumor pain occur patient clinic
signific treatment-emerg advers event report
cytokin releas syndrom infusion-rel reaction typic occur first dose
step-up incid sever decreas increas exposur modif
pre-med drug administr reduc frequenc sever infus
reaction cytokin releas syndrom
on-going phase combin antibodi
regeneron enrol open-label dose-escal studi evalu
combin investig therapi
relapse/refractori lymphoma patient patient nhl hl enrol
across site us germani spain patient diseas prior anti-pd-
therapi allogen stem cell transplant exclud primari endpoint
incid treatment-emerg advers event week studi expect
complet june accord clinicaltri gov
advanc preclin etb candid base potent
de-immun second-gener scaffold compound discov jointli
takeda compani releas data compound
present preclin data predecessor etb-bas compound data
demonstr potent cell-kil activ tumor cell
picomolar valu improv slt-a immunogen compar first-gener
scaffold vivo activ clinic valid xenograft model
potenti synergi pomalidomid
compound still earli develop believ strong rational
efficaci patient progress diseas follow treatment first-gener anti-
antibodi daratumumab nhl patient multipl studi
demonstr mani multipl myeloma patient retain express despit
fail daratumumab addit potenti synergi pomalidomid open
potenti treatment patient less advanc multipl myeloma
expect drug launch us outsid us
net forecast translat peak sale includ us sale
intern royalti gross sale believ drug
may eventu achiev sale greater annual
overview target multipl myeloma
single-chain type ii transmembran glycoprotein express across varieti
hematolog cell includ multipl myeloma case addit
also commonli express nhl aml b-cell cll albeit lesser extent
intern effici
valid clinic meaning target multipl myeloma
novemb fda approv mab darzalex daratumumab
relapsed/refractori multipl myeloma least prior line therapi subsequ
fda approv darzalex combin revlimid lenalidomid /dexamethason
velcad bortezomid /dexamethason second-lin relapsed/refractori multipl
myeloma novemb combin pomalyst pomalidomid third-
line r/r multipl myeloma drug approv frontlin set may
johnson johnson report sale first nine month
importantli analysi express level pivot fourth-lin
relapsed/refractori multipl myeloma cohort treat daratumumab publish
journal blood june indic express bone marrow circul
multipl myeloma cell restor follow discontinu daratumumab
addit analysi highlight upregul complement-inhibitori protein cip
associ daratumumab resist progress
take resist first-gener antibodi daratumumab appear
mediat preclin studi predecessor etb-bas
compound highli potent cell co-express
clinic regulatori overview
develop plan like mirror daratumumab view
base case call phase studi line
patient phase evalu daratumumab approv like base orr
patient treat expect commerci dose relapsed/refractori set
take studi orr primari endpoint adequ
support regulatori file relapsed/refractori multipl myeloma
point refer single-ag daratumumab approv fda treatment
multipl myeloma patient fail least three prior line therapi primarili base
orr report among patient treat approv dose
phase i/ii siriu trial month median durat respons
month report investig
revenu forecast focus relapsed/refractori multipl myeloma base
well-defin activ therapeut unmet medic need salvag
set depend safeti profil may clinic rational move
compound earlier multipl myeloma treatment paradigm evalu use
hematolog solid tumor indic revisit assumpt follow
present clinic safeti data like late segment revenu
us row us market repres market opportun base
clear regulatori reimburs path
american diagnos multipl myeloma year accord
american cancer societi among us multipl myeloma patient initi first-
line therapi initi second- third- fourth-lin therapi
within month base retrospect analysi truven health marketscan
commerci medicar databas jan may
publish blood model target third-lin relapsed/refractori
popul roughli patient fourth-lin popul patient
target address popul patient
expect captur target us relapsed/refractori multipl myeloma
salvag market base potenti improv safeti profil versu bispecif antibodi
expect price annual per one-month
treatment cycl us line annual cost darzalex pomalyst
respect
assum dose continu diseas progress believ
improv compar month darzalax month report
pomalyst would minimum efficaci threshold support
commerci assum patient receiv monthli cycl
averag cost per patient us
royalti rate agreement takeda disclos howev estim
receiv econom equival royalti net sale point
estim methodolog point includ partner mileston
revenu model due limit visibl time rather captur mileston econom
assum higher royalti rate futur sale model assum
opt co-develop fund commit opt prior
commerci futur royalti rate reduc
expect drug launch us outsid us
net forecast translat peak sale includ us sale
intern royalti gross sale believ drug
may eventu achiev sale greater annual
daratumumab antibodi develop genmab sold johnson
johnson darzalex drug steadili gain market share base data
demonstr impress clinic activ earlier line therapi expect sale
growth continu next year base approv may
daratumumab newli diagnos multipl myeloma patient inelig autolog
stem cell transplant combin bortezomib melphalan prednison vmp
upbeat outlook base larg measur preclin data
demonstr mani patient report diseas progress daratumumab
retain express loss primari mechan daratumumab
resist patient addit believ opportun combin two
molecul explor base potenti target differ
bind domain reduc risk resist
take greater use daratumumab increas address refractori multipl
myeloma popul use combin daratumumab first-
second-lin therapi could add upsid potenti outlook
result build data phase alcyon studi
month median follow-up daratumumab led reduct risk progress
death hr ci benefit consist
across pre-defin subgroup median reach daratumumab vs
month control orr vs significantli higher
r/r multipl myeloma market modelamerican diagnos mm project growth mm number mm mm patient initi r/r mm patient mm patient initi r/r mm patient mm patient initi r/r mm patient r/r mm popul target mm popul receiv patient script per per treatment per price per sale r/r multipl myeloma row gross revenu growth row sale revenu outperform
novemb fda approv daratumumab combin lenalidomid
dexamethason bortezomib dexamethason second-lin
relapsed/refractori multipl myeloma approv base interim data phase
pollux castor studi demonstr lower risk progress
death respect daratumumab receiv fda breakthrough design
second-lin relapse/refractori multipl myeloma juli
least prior line therapi daratumumab combin lenalidomid
dexamethason lenalidomid dexamethason alon patient receiv median
prior therapi rang receiv prior line
receiv asct refractori diseas primari endpoint
highlight interim data support approv publish new england journal
medicin risk progress death lower daratumumab arm
trial hr ci cross pre-specifi stop
boundari median follow-up month median reach
daratumumab cohort versu month control estim rate
ci ci daratumumab control
benefit daratumumab observ regardless prior line therapi
orr significantli higher daratumumab control vs
includ good pr better vs two-fold
greater cr better vs daratumumab patient
met mrd-neg threshold compar control
overal combin safeti profil larg consist lenalidomid
dexamethason except increas neutropenia infusion-rel reaction advers
event occur frequenc grade/grad
cough vs grade thrombocytopenia occur
daratumumab control respect seriou advers event
occur daratumumab control patient respect
data cutoff daratumumab-tr patient discontinu therapi due advers
myeloma patient least prior line therapi receiv daratumumab bortezomib
dexamethason combin bortezomib dexamethason random
patient receiv median prior therapi rang receiv
asct refractori diseas primari endpoint
highlight interim data support approv publish nejm risk
progress death lower daratumumab arm hr ci
cross pre-specifi stop boundari median follow-up
month median reach daratumumab cohort ci na
versu month control ci estim rate
ci ci daratumumab control
respect benefit daratumumab observ regardless prior line
orr significantli higher daratumumab control vs
includ good pr better vs two-fold
greater cr better vs overal combin safeti profil
larg consist bortezomib dexamethason except increas
neutropenia infusion-rel reaction
daratumumab combin associ higher rate grade advers
event vs common grade advers event report
daratumumab control thrombocytopenia anemia
neutropenia rate grade infect
similar treatment arm
june fda approv daratumumab combin pomalidomid
dexamethason relapsed/refractori multipl myeloma patient fail least
two prior therapi includ lenalidomid proteasom inhibitor approv
base data open-label phase equuleu studi janssen unit johnson
 johnson initi random phase apollo studi
confirm equuleu result apollo conduct europ evalu
primari endpoint relapsed/refractori multipl myeloma follow
immunomodulatori imid drug imid proteasom inhibit pi treatment
total relapsed/refractori multipl myeloma patient enrol onto phase
equuleu studi receiv daratumumab combin pomalidomid
dexamethason safeti primari endpoint orr minim residu diseas
secondari outcom patient receiv median prior therapi rang
receiv least prior treatment
orr includ orr double-refractori patient publish
blood better mrd-neg median follow-
month median month ci median surviv
month ci na median durat respons achiev
ci na estim overal surviv rate ci
safeti profil combin gener consist previous observ
monotherapi safeti profil increas neutropenia observ lead
increas infect rate common grade higher advers event includ
neutropenia anemia leukopenia
novemb daratumumab receiv acceler approv monotherapi r/r
mm patient least prior therapi includ proteasom inhibitor
immunomodulatori agent double-refractori proteasom inhibitor
immunomodulatori agent acceler approv support data open-
label phase ii siriu studi includ orr daratumumab receiv
breakthrough design fourth-lin relapse/refractori multipl myeloma may
open-label phase ii siriu studi dose patient fda-approv dose
daratumumab patient receiv median line therapi rang
includ prior asct refractori recent therapi
report journal lancet orr ci rate scr
ci good pr ci pr
ci median month ci median
durat respons month ci na twelve-month overal surviv
ci
patient discontinu therapi due daratumumab-rel toxic fatigu
anemia commonli report event grade
next-gener etb target expand portfolio
mention develop etb-bas therapi valid
cancer target novel cancer target strong preclin
rational potent activ limit clinic valid compound
highlight compani early-stag program proven target
novel target bcma
program preclin develop disclos timelin ind file
limit publish preclin potenc profil base second-gener
etb scaffold includ econom program financi
forecast valuat revisit assumpt upon ind file
seed drive i/o
meet present poster entitl antigen seed
technolog engin toxin bodi provid target immuno-oncolog approach
treatment cancer poster describ preclin activ
immunodomin restrict peptid nlvpmvatv cmv tegument
combin second-gener deimmun shiga toxin
backbon design promot forc cell intern find includ
addit cmv antigen chang cell bind affin shiga-lik toxin direct
cell-kil activ increas ifn-gamma secret cell lysi observ
direct cell-kil mechan genet remov compound suggest
antigen seed activ co-cultur cell line without
express express confirm necessari activ mt-
develop base expect compound would gener strong t-
cell respons roughli adult cell memori cmv moa
requir level tumor cell activ inhibitor mt-
could particular clinic valu so-cal cold tumor tumor low
mutat burden patient refractori first-lin checkpoint inhibitor
view
mtem lead etb preclin develop potenti treatment
metastat breast cancer target demonstr clinic benefit
multipl histolog express shown persist failur
modal notabl direct cell-kil approach valid
fda februari approv kadcyla ado-trastuzumab
emtansin report new england journal medicin kadcyla led median
month versu month lapatinib plu capecitabin orr
versu control roch report kadcyla sale chf
includ us sale chf
preclin studi demonstr picomolar activ kadcyla insensit
cell line well addit synergist benefit kadcyla cell
line accord manag
evofosfamid prodrug bromo-isophosphoramid mustard br-ipm dna
alkyl agent design preferenti activ hypox region commonli present
tumor microenviron activ within hypox tumor environ br-
ipm form dna crosslink inhibit dna replic interfer protein
transcript secondarili br-ipm demonstr potenti diffus surround
oxygen region tumor kill cell via bystand effect
evofosfamid evalu monotherapi part combin regimen
patient variou cancer histolog includ fail phase studi
pancreat cancer soft tissu sarcoma base case call newli initi
evofosfamid clinic develop fund non-dilut sourc
take exposur patient confirm safeti profil potenc
monotherapi demonstr given establish efficaci profil
alkyl agent studi combin therapi justifi believ
clinic develop histori pancreat cancer
gemcitabin previous untreat local advanc unresect metastat
pancreat adenocarcinoma clinic trial enrol patient primari endpoint
overal surviv secondari endpoint includ orr diseas control rate
safeti evalu biomark patient receiv evofosfamid achiev median
surviv month versu month control hr ci
manag attribut outcom longer expect surviv
control arm evofosfamid significantli improv median vs month hr
ci orr vs ci
take evofosfamid demonstr efficaci signal challeng set
front-lin pancreat cancer signal enhanc efficaci subset analysi
asian patient may warrant studi
previous phase iib studi evalu gemcitabin plu evofosfamid
placebo treatment first-lin pancreat cancer studi enrol patient
us site assess result publish journal clinic oncolog
demonstr month improv overal surviv
vs control arm patient treat high-dos evofosfamid
common advers event relat evofosfamid skin
mucos toxic predominantli grade myelosuppress
june md anderson cancer center dose first patient single-cent
phase clinic trial evalu evofosfamid plu ipilimumab treatment
refractori advanc solid malign accord clinicaltri gov studi
complet
rational studi base potenti combin regimen reduc
hypoxia-associ suppressor cell populationsmyeloid-deriv regulatori cell
increas cell respons tumor antigen drain lymph node improv
cell penetr tumor preclin research conduct md anderson
demonstr strong addit anti-canc activ evofosfamid plu checkpoint
take studi properli design evalu potenti benefit ad
hypoxia-target cytotox agent evofosfamid immun checkpoint inhibitor
current econom evofosfamid financi forecast
open-label single-arm dose-escal studi enrol patient ecog score
measur diseas per irrecist patient castrate-resist prostat cancer
measur evalu diseas accept laboratori paramet
dose escal complet four cohort enrol metastat local
advanc prostat cancer metastat pancreat cancer melanoma hpv-
neg squamou cell carcinoma head neck total studi dose
adult onto dose-escal onto disease-specif
expans cohort patient exposur prior immune-oncolog therapi
elig studi subject prior grade ipilimumab
exhibit evofosfamid ipilimumab dose schedul
enrol patient treat total four dose cycl evofosfamid
dose day combin ipilimumab day first cycl
ipilimumab dose alon day last cycl cohort receiv
escal evofosfamid dose level via minut iv infus
ipilimumab stabl via minut iv infus primari endpoint
recommend phase ii dose secondari efficaci outcom includ orr per
irrecist peripher blood tumor tissu immun hypoxia paramet
evalu potenti biomark
current use hybrid strategi invest signific intern expertis process
develop outsourc gmp manufactur compani provid
limit disclosur regard manufactur process pipelin program
